These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25418144)

  • 21. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
    Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S; Stein K; Kotulska K
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
    J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
    Zipori AB; Tehrani NN; Ali A
    J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus.
    Laviv Y; Jackson S; Rappaport ZH
    Acta Neurochir (Wien); 2015 Feb; 157(2):241-5. PubMed ID: 25524658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors.
    Danassegarane G; Tinois J; Sahler Y; Aouaissia S; Riffaud L
    Neurochirurgie; 2022 Dec; 68(6):627-636. PubMed ID: 35907444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
    Jóźwiak S; Nabbout R; Curatolo P;
    Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
    Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
    Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.
    Jóźwiak S; Mandera M; Młynarski W
    Semin Pediatr Neurol; 2015 Dec; 22(4):274-81. PubMed ID: 26706014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas.
    Moavero R; Carai A; Mastronuzzi A; Marciano S; Graziola F; Vigevano F; Curatolo P
    Pediatr Neurol; 2017 Mar; 68():59-63. PubMed ID: 28162859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Jia J; Xiong L; Chen S
    N Engl J Med; 2011 Feb; 364(6):577. PubMed ID: 21306252
    [No Abstract]   [Full Text] [Related]  

  • 36. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S; Hawkins C; Taylor MD; Bartels U
    Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study).
    Trelinska J; Dachowska I; Baranska D; Stawiski K; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27860334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
    Arroyo MS; Krueger DA; Broomall E; Stevenson CB; Franz DN
    Pediatr Neurol; 2017 Jul; 72():81-85. PubMed ID: 28511812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.